nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—Hepatic cirrhosis—Furosemide—dilated cardiomyopathy	0.0348	0.0526	CcSEcCtD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL2—dilated cardiomyopathy	0.0209	0.0619	CbGpPWpGaD
Maraviroc—Tetany—Furosemide—dilated cardiomyopathy	0.0205	0.031	CcSEcCtD
Maraviroc—Drug eruption—Spironolactone—dilated cardiomyopathy	0.02	0.0301	CcSEcCtD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCR3—dilated cardiomyopathy	0.0194	0.0575	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0167	0.0495	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.0156	0.046	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0147	0.0434	CbGpPWpGaD
Maraviroc—Abdominal bloating—Furosemide—dilated cardiomyopathy	0.014	0.0212	CcSEcCtD
Maraviroc—CCR5—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.0132	0.039	CbGpPWpGaD
Maraviroc—Ulcer—Spironolactone—dilated cardiomyopathy	0.013	0.0196	CcSEcCtD
Maraviroc—CCR5—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.0129	0.0381	CbGpPWpGaD
Maraviroc—Vasculitis—Spironolactone—dilated cardiomyopathy	0.0126	0.019	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—FASLG—dilated cardiomyopathy	0.0119	0.0351	CbGpPWpGaD
Maraviroc—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.0116	0.0175	CcSEcCtD
Maraviroc—Drug eruption—Furosemide—dilated cardiomyopathy	0.0109	0.0164	CcSEcCtD
Maraviroc—CCR5—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.0103	0.0306	CbGpPWpGaD
Maraviroc—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00965	0.0146	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—FAS—dilated cardiomyopathy	0.00827	0.0245	CbGpPWpGaD
Maraviroc—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00802	0.0121	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00787	0.0233	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00787	0.0233	CbGpPWpGaD
Maraviroc—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00762	0.0115	CcSEcCtD
Maraviroc—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.0076	0.0115	CcSEcCtD
Maraviroc—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00742	0.0112	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00732	0.0216	CbGpPWpGaD
Maraviroc—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00695	0.0105	CcSEcCtD
Maraviroc—Vasculitis—Furosemide—dilated cardiomyopathy	0.00684	0.0103	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00681	0.0103	CcSEcCtD
Maraviroc—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00677	0.0102	CcSEcCtD
Maraviroc—Renal failure—Spironolactone—dilated cardiomyopathy	0.00675	0.0102	CcSEcCtD
Maraviroc—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00665	0.0101	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00664	0.0196	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00664	0.0196	CbGpPWpGaD
Maraviroc—Otitis media—Lisinopril—dilated cardiomyopathy	0.00644	0.00972	CcSEcCtD
Maraviroc—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00641	0.00968	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00617	0.0183	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00616	0.0182	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00605	0.0179	CbGpPWpGaD
Maraviroc—Urine output increased—Furosemide—dilated cardiomyopathy	0.00604	0.00912	CcSEcCtD
Maraviroc—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00583	0.0088	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00573	0.0169	CbGpPWpGaD
Maraviroc—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.0057	0.00861	CcSEcCtD
Maraviroc—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0057	0.00861	CcSEcCtD
Maraviroc—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00562	0.0085	CcSEcCtD
Maraviroc—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00557	0.00842	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00555	0.0164	CbGpPWpGaD
Maraviroc—Polyuria—Furosemide—dilated cardiomyopathy	0.00552	0.00834	CcSEcCtD
Maraviroc—Alopecia—Spironolactone—dilated cardiomyopathy	0.00545	0.00823	CcSEcCtD
Maraviroc—Oliguria—Lisinopril—dilated cardiomyopathy	0.00544	0.00821	CcSEcCtD
Maraviroc—Deafness—Furosemide—dilated cardiomyopathy	0.00542	0.00819	CcSEcCtD
Maraviroc—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00542	0.00819	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.00537	0.0159	CbGpPWpGaD
Maraviroc—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00537	0.00811	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00528	0.0156	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00528	0.0156	CbGpPWpGaD
Maraviroc—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00514	0.00776	CcSEcCtD
Maraviroc—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00513	0.00776	CcSEcCtD
Maraviroc—Purpura—Furosemide—dilated cardiomyopathy	0.00503	0.0076	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00491	0.0145	CbGpPWpGaD
Maraviroc—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00487	0.00735	CcSEcCtD
Maraviroc—Leukopenia—Spironolactone—dilated cardiomyopathy	0.0048	0.00726	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00475	0.0141	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00474	0.014	CbGpPWpGaD
Maraviroc—Discomfort—Spironolactone—dilated cardiomyopathy	0.00451	0.00682	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.0045	0.0133	CbGpPWpGaD
Maraviroc—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00443	0.00669	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00437	0.00659	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00426	0.0126	CbGpPWpGaD
Maraviroc—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00422	0.00637	CcSEcCtD
Maraviroc—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.0042	0.00635	CcSEcCtD
Maraviroc—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00418	0.00632	CcSEcCtD
Maraviroc—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00415	0.00627	CcSEcCtD
Maraviroc—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00411	0.00621	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00406	0.012	CbGpPWpGaD
Maraviroc—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00405	0.00611	CcSEcCtD
Maraviroc—Eczema—Lisinopril—dilated cardiomyopathy	0.00405	0.00611	CcSEcCtD
Maraviroc—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00403	0.00609	CcSEcCtD
Maraviroc—CCR5—HIV Infection—RAC1—dilated cardiomyopathy	0.00402	0.0119	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00402	0.0119	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00402	0.0119	CbGpPWpGaD
Maraviroc—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00399	0.00603	CcSEcCtD
Maraviroc—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00394	0.00595	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00385	0.0114	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00378	0.00571	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00374	0.0111	CbGpPWpGaD
Maraviroc—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00371	0.00561	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.0037	0.00559	CcSEcCtD
Maraviroc—Renal failure—Furosemide—dilated cardiomyopathy	0.00367	0.00555	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00362	0.0107	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00359	0.0106	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00353	0.00534	CcSEcCtD
Maraviroc—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00349	0.00527	CcSEcCtD
Maraviroc—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00346	0.00523	CcSEcCtD
Maraviroc—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00332	0.00502	CcSEcCtD
Maraviroc—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00331	0.005	CcSEcCtD
Maraviroc—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00329	0.00497	CcSEcCtD
Maraviroc—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00329	0.00497	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00328	0.00495	CcSEcCtD
Maraviroc—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00325	0.00491	CcSEcCtD
Maraviroc—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00323	0.00487	CcSEcCtD
Maraviroc—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00317	0.00479	CcSEcCtD
Maraviroc—Influenza—Lisinopril—dilated cardiomyopathy	0.00314	0.00475	CcSEcCtD
Maraviroc—Eye disorder—Furosemide—dilated cardiomyopathy	0.00313	0.00473	CcSEcCtD
Maraviroc—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00311	0.0047	CcSEcCtD
Maraviroc—Pruritus—Spironolactone—dilated cardiomyopathy	0.0031	0.00468	CcSEcCtD
Maraviroc—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00309	0.00467	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00309	0.00915	CbGpPWpGaD
Maraviroc—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00308	0.00466	CcSEcCtD
Maraviroc—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00306	0.00463	CcSEcCtD
Maraviroc—Angiopathy—Furosemide—dilated cardiomyopathy	0.00304	0.0046	CcSEcCtD
Maraviroc—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00302	0.00457	CcSEcCtD
Maraviroc—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.003	0.00453	CcSEcCtD
Maraviroc—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00299	0.00451	CcSEcCtD
Maraviroc—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00294	0.00444	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00293	0.00868	CbGpPWpGaD
Maraviroc—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00292	0.00441	CcSEcCtD
Maraviroc—Erythema—Furosemide—dilated cardiomyopathy	0.00292	0.00441	CcSEcCtD
Maraviroc—Malnutrition—Furosemide—dilated cardiomyopathy	0.00292	0.00441	CcSEcCtD
Maraviroc—Dizziness—Spironolactone—dilated cardiomyopathy	0.0029	0.00437	CcSEcCtD
Maraviroc—Flatulence—Furosemide—dilated cardiomyopathy	0.00288	0.00435	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00286	0.00845	CbGpPWpGaD
Maraviroc—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00282	0.00426	CcSEcCtD
Maraviroc—Depression—Lisinopril—dilated cardiomyopathy	0.00279	0.00422	CcSEcCtD
Maraviroc—Vomiting—Spironolactone—dilated cardiomyopathy	0.00278	0.00421	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00278	0.0042	CcSEcCtD
Maraviroc—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00276	0.00417	CcSEcCtD
Maraviroc—Rash—Spironolactone—dilated cardiomyopathy	0.00276	0.00417	CcSEcCtD
Maraviroc—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00276	0.00417	CcSEcCtD
Maraviroc—Renal failure—Lisinopril—dilated cardiomyopathy	0.00276	0.00416	CcSEcCtD
Maraviroc—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00275	0.00415	CcSEcCtD
Maraviroc—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00275	0.00415	CcSEcCtD
Maraviroc—Headache—Spironolactone—dilated cardiomyopathy	0.00274	0.00414	CcSEcCtD
Maraviroc—Jaundice—Lisinopril—dilated cardiomyopathy	0.00273	0.00413	CcSEcCtD
Maraviroc—Anaemia—Furosemide—dilated cardiomyopathy	0.0027	0.00408	CcSEcCtD
Maraviroc—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00265	0.004	CcSEcCtD
Maraviroc—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00263	0.00397	CcSEcCtD
Maraviroc—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00262	0.00395	CcSEcCtD
Maraviroc—Leukopenia—Furosemide—dilated cardiomyopathy	0.00261	0.00395	CcSEcCtD
Maraviroc—Nausea—Spironolactone—dilated cardiomyopathy	0.0026	0.00393	CcSEcCtD
Maraviroc—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00252	0.00381	CcSEcCtD
Maraviroc—Hallucination—Lisinopril—dilated cardiomyopathy	0.0025	0.00378	CcSEcCtD
Maraviroc—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.0025	0.00377	CcSEcCtD
Maraviroc—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00248	0.00375	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00247	0.00373	CcSEcCtD
Maraviroc—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00247	0.00373	CcSEcCtD
Maraviroc—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00238	0.00359	CcSEcCtD
Maraviroc—Shock—Furosemide—dilated cardiomyopathy	0.00234	0.00354	CcSEcCtD
Maraviroc—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00234	0.00353	CcSEcCtD
Maraviroc—Skin disorder—Furosemide—dilated cardiomyopathy	0.00231	0.0035	CcSEcCtD
Maraviroc—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00228	0.00345	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00227	0.00672	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00227	0.00672	CbGpPWpGaD
Maraviroc—Anorexia—Furosemide—dilated cardiomyopathy	0.00227	0.00343	CcSEcCtD
Maraviroc—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00227	0.00343	CcSEcCtD
Maraviroc—Alopecia—Lisinopril—dilated cardiomyopathy	0.00222	0.00336	CcSEcCtD
Maraviroc—Mental disorder—Lisinopril—dilated cardiomyopathy	0.0022	0.00333	CcSEcCtD
Maraviroc—Erythema—Lisinopril—dilated cardiomyopathy	0.00219	0.00331	CcSEcCtD
Maraviroc—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00219	0.00331	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00218	0.00644	CbGpPWpGaD
Maraviroc—Flatulence—Lisinopril—dilated cardiomyopathy	0.00216	0.00326	CcSEcCtD
Maraviroc—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00214	0.00323	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00211	0.00625	CbGpPWpGaD
Maraviroc—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00207	0.00313	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00206	0.0061	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00206	0.0061	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00206	0.00311	CcSEcCtD
Maraviroc—Fatigue—Furosemide—dilated cardiomyopathy	0.00205	0.0031	CcSEcCtD
Maraviroc—Tremor—Lisinopril—dilated cardiomyopathy	0.00205	0.0031	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00205	0.00605	CbGpPWpGaD
Maraviroc—Constipation—Furosemide—dilated cardiomyopathy	0.00204	0.00308	CcSEcCtD
Maraviroc—Pain—Furosemide—dilated cardiomyopathy	0.00204	0.00308	CcSEcCtD
Maraviroc—Anaemia—Lisinopril—dilated cardiomyopathy	0.00202	0.00306	CcSEcCtD
Maraviroc—CCR5—Disease—NPPA—dilated cardiomyopathy	0.00202	0.00599	CbGpPWpGaD
Maraviroc—Syncope—Lisinopril—dilated cardiomyopathy	0.00196	0.00297	CcSEcCtD
Maraviroc—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00196	0.00296	CcSEcCtD
Maraviroc—CCR5—Disease—PSEN2—dilated cardiomyopathy	0.00196	0.0058	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00195	0.00294	CcSEcCtD
Maraviroc—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00193	0.00291	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00192	0.00568	CbGpPWpGaD
Maraviroc—Cough—Lisinopril—dilated cardiomyopathy	0.00191	0.00289	CcSEcCtD
Maraviroc—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00188	0.00285	CcSEcCtD
Maraviroc—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00188	0.00285	CcSEcCtD
Maraviroc—Myalgia—Lisinopril—dilated cardiomyopathy	0.00186	0.00282	CcSEcCtD
Maraviroc—Anxiety—Lisinopril—dilated cardiomyopathy	0.00186	0.00281	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00186	0.0055	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00185	0.0028	CcSEcCtD
Maraviroc—Discomfort—Lisinopril—dilated cardiomyopathy	0.00184	0.00278	CcSEcCtD
Maraviroc—Oedema—Lisinopril—dilated cardiomyopathy	0.00179	0.0027	CcSEcCtD
Maraviroc—Infection—Lisinopril—dilated cardiomyopathy	0.00178	0.00268	CcSEcCtD
Maraviroc—Shock—Lisinopril—dilated cardiomyopathy	0.00176	0.00266	CcSEcCtD
Maraviroc—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00176	0.00265	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00175	0.00517	CbGpPWpGaD
Maraviroc—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00174	0.00262	CcSEcCtD
Maraviroc—Asthenia—Furosemide—dilated cardiomyopathy	0.00171	0.00258	CcSEcCtD
Maraviroc—Anorexia—Lisinopril—dilated cardiomyopathy	0.0017	0.00257	CcSEcCtD
Maraviroc—Pruritus—Furosemide—dilated cardiomyopathy	0.00169	0.00255	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00166	0.0049	CbGpPWpGaD
Maraviroc—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00163	0.00246	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00163	0.00246	CcSEcCtD
Maraviroc—Insomnia—Lisinopril—dilated cardiomyopathy	0.00162	0.00244	CcSEcCtD
Maraviroc—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00161	0.00242	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00159	0.00469	CbGpPWpGaD
Maraviroc—Dizziness—Furosemide—dilated cardiomyopathy	0.00158	0.00238	CcSEcCtD
Maraviroc—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00155	0.00235	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00154	0.00233	CcSEcCtD
Maraviroc—Fatigue—Lisinopril—dilated cardiomyopathy	0.00154	0.00233	CcSEcCtD
Maraviroc—Pain—Lisinopril—dilated cardiomyopathy	0.00153	0.00231	CcSEcCtD
Maraviroc—Constipation—Lisinopril—dilated cardiomyopathy	0.00153	0.00231	CcSEcCtD
Maraviroc—Vomiting—Furosemide—dilated cardiomyopathy	0.00151	0.00229	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00151	0.00445	CbGpPWpGaD
Maraviroc—Rash—Furosemide—dilated cardiomyopathy	0.0015	0.00227	CcSEcCtD
Maraviroc—Dermatitis—Furosemide—dilated cardiomyopathy	0.0015	0.00227	CcSEcCtD
Maraviroc—Headache—Furosemide—dilated cardiomyopathy	0.00149	0.00225	CcSEcCtD
Maraviroc—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00146	0.00221	CcSEcCtD
Maraviroc—Nausea—Furosemide—dilated cardiomyopathy	0.00142	0.00214	CcSEcCtD
Maraviroc—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00141	0.00213	CcSEcCtD
Maraviroc—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00141	0.00213	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00137	0.00406	CbGpPWpGaD
Maraviroc—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00132	0.00199	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00129	0.00381	CbGpPWpGaD
Maraviroc—Asthenia—Lisinopril—dilated cardiomyopathy	0.00128	0.00194	CcSEcCtD
Maraviroc—Pruritus—Lisinopril—dilated cardiomyopathy	0.00126	0.00191	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00123	0.00364	CbGpPWpGaD
Maraviroc—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00122	0.00185	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00122	0.00361	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00122	0.00361	CbGpPWpGaD
Maraviroc—Dizziness—Lisinopril—dilated cardiomyopathy	0.00118	0.00179	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.00117	0.00346	CbGpPWpGaD
Maraviroc—Vomiting—Lisinopril—dilated cardiomyopathy	0.00114	0.00172	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00113	0.00335	CbGpPWpGaD
Maraviroc—Rash—Lisinopril—dilated cardiomyopathy	0.00113	0.0017	CcSEcCtD
Maraviroc—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00113	0.0017	CcSEcCtD
Maraviroc—Headache—Lisinopril—dilated cardiomyopathy	0.00112	0.00169	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00112	0.0033	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.0011	0.00325	CbGpPWpGaD
Maraviroc—Nausea—Lisinopril—dilated cardiomyopathy	0.00106	0.0016	CcSEcCtD
Maraviroc—CCR5—Disease—RAC1—dilated cardiomyopathy	0.000986	0.00292	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000937	0.00277	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000889	0.00263	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000775	0.00229	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000764	0.00226	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAC1—dilated cardiomyopathy	0.00069	0.00204	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGT—dilated cardiomyopathy	0.00066	0.00195	CbGpPWpGaD
Maraviroc—CCR5—Disease—RAF1—dilated cardiomyopathy	0.000654	0.00193	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000531	0.00157	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000458	0.00135	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—dilated cardiomyopathy	0.000448	0.00133	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000314	0.000929	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.00029	0.000859	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000273	0.000807	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000247	0.00073	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	6.7e-05	0.000198	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	6.53e-05	0.000193	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.88e-05	0.000174	CbGpPWpGaD
